Sectors
TSHA
Taysha Gene Therapies, Inc.
5.02
2 x 3.71
2 x 6.40
bid
ask
-
0.14
2.71%
2 @ 07:30 PM
5.02 +0.00 (0.00%)
| Ytd | -8.73% | |
| 1y | 67.89% |
4.96
day range
5.28
2.83
52 week range
6.98
| Open | 5.16 | Prev Close | 5.16 | Low | 4.96 | High | 5.28 | Mkt Cap | 1.64B |
| Vol | 9.12M | Avg Vol | 3.17M | EPS | -0.41 | P/E | N/A | Forward P/E | -10.85 |
| Beta | 1.17 | Short Ratio | 18.16 | Inst. Own | 94.29% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 5.84 | 200-d Avg | 5.47 | 1yr Est | 13.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-03 | 2026-09 | -0.14 | N/A | N/A | N/A |
| 2026-08-11 | 2026-06 | -0.11 | -0.13 | -0.02 | -14.77% |
| 2026-05-06 | 2026-03 | -0.1 | -0.12 | -0.02 | -20.00% |
| 2026-03-19 | 2025-12 | -0.11 | -0.08 | 0.03 | 27.27% |
| 2025-11-04 | 2025-09 | -0.09 | -0.09 | N/A | N/A |
| 2025-08-12 | 2025-06 | -0.07 | -0.09 | -0.02 | -28.57% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-17 | Wolfe Research | Upgrade | Outperform | |
| 2026-07-21 | Goldman Sachs | Upgrade | Buy | Buy |
| 2026-07-02 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-06-30 | Needham | Upgrade | Buy | Buy |
| 2026-06-30 | Baird | Upgrade | Outperform | Outperform |
| 2026-06-23 | BMO Capital | Upgrade | Outperform | Outperform |
Profile
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-03 | ALAM KAMRAN | Chief Financial Officer | 1.44M | Sale |
| 2026-05-31 | DONENBERG PHILLIP BRIAN | Director | 241.29K | Stock Award(Grant) |
| 2026-05-31 | LONG ALISON S | Director | 127.18K | Stock Award(Grant) |
| 2025-05-29 | MANNING PAUL B. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-07-09 | NAGENDRAN SUKUMAR | Officer and Director | 936.41K | Sale |
| 2026-01-25 | NOLAN SEAN PATRICK | Chief Executive Officer | 4.44M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Avoro Capital Advisors LLC | 23.89M | 119.92M | 7.33% |
| 2026-06-29 | RA Capital Management, L.P. | 23.56M | 118.25M | 7.23% |
| 2026-06-29 | Goldman Sachs Group Inc | 22.71M | 114.02M | 6.97% |
| 2026-06-29 | Blackrock Inc. | 20.69M | 103.87M | 6.35% |
| 2026-06-29 | Vestal Point Capital, LP | 19.42M | 97.46M | 5.96% |
| 2026-06-29 | Morgan Stanley | 16.49M | 82.77M | 5.06% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 9.14M | 45.87M | 2.80% |
| 2026-07-30 | iShares Trust-iShares Russell 2000 ETF | 6.11M | 30.67M | 1.88% |
| 2026-07-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 5.47M | 27.44M | 1.68% |
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.17M | 20.94M | 1.28% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 3.04M | 15.28M | 0.93% |
| 2026-06-29 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 2.60M | 13.05M | 0.80% |